JP2022512778A5 - - Google Patents

Info

Publication number
JP2022512778A5
JP2022512778A5 JP2021521765A JP2021521765A JP2022512778A5 JP 2022512778 A5 JP2022512778 A5 JP 2022512778A5 JP 2021521765 A JP2021521765 A JP 2021521765A JP 2021521765 A JP2021521765 A JP 2021521765A JP 2022512778 A5 JP2022512778 A5 JP 2022512778A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
acid sequence
seq
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521765A
Other languages
English (en)
Japanese (ja)
Other versions
JP7669269B2 (ja
JP2022512778A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058971 external-priority patent/WO2020092654A1/en
Publication of JP2022512778A publication Critical patent/JP2022512778A/ja
Publication of JP2022512778A5 publication Critical patent/JP2022512778A5/ja
Application granted granted Critical
Publication of JP7669269B2 publication Critical patent/JP7669269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521765A 2018-10-30 2019-10-30 抗-cd45抗体及びそのコンジュゲート Active JP7669269B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862753002P 2018-10-30 2018-10-30
US62/753,002 2018-10-30
US201862774006P 2018-11-30 2018-11-30
US62/774,006 2018-11-30
US201962807582P 2019-02-19 2019-02-19
US62/807,582 2019-02-19
PCT/US2019/058971 WO2020092654A1 (en) 2018-10-30 2019-10-30 Anti-cd45 antibodies and conjugates thereof

Publications (3)

Publication Number Publication Date
JP2022512778A JP2022512778A (ja) 2022-02-07
JP2022512778A5 true JP2022512778A5 (cg-RX-API-DMAC7.html) 2022-11-07
JP7669269B2 JP7669269B2 (ja) 2025-04-28

Family

ID=70463930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521765A Active JP7669269B2 (ja) 2018-10-30 2019-10-30 抗-cd45抗体及びそのコンジュゲート

Country Status (7)

Country Link
US (1) US12291576B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877416A4 (cg-RX-API-DMAC7.html)
JP (1) JP7669269B2 (cg-RX-API-DMAC7.html)
CN (1) CN113302203A (cg-RX-API-DMAC7.html)
AU (1) AU2019370367A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117367A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020092654A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200376135A1 (en) * 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
JP2022518150A (ja) * 2019-01-07 2022-03-14 マジェンタ セラピューティクス インコーポレイテッド 細胞療法での抗cd45抗体-薬物結合体(adc)の使用経験
WO2020219959A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd45 antibody drug conjugates and uses thereof
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
GB202015226D0 (en) * 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
GB202015235D0 (en) * 2020-09-25 2020-11-11 Ucl Business Plc Anti-CD45 antibodies and related therapeutics
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス,インコーポレイテッド プロテアーゼ活性化cd45ゲートcar
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
EP4637928A1 (en) * 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
KR20250065477A (ko) * 2023-11-03 2025-05-13 고려대학교 산학협력단 작용기 기능이 제거된 Fab-arm 교환 방지 Fc 변이체들
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN119874942B (zh) * 2025-03-28 2025-09-26 核欣(苏州)医药科技有限公司 一种放射性蛋白偶联药物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574804A (en) * 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
CA2904806C (en) * 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
US9631024B2 (en) * 2014-06-23 2017-04-25 Bionomics, Inc. Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017044308A1 (en) * 2015-09-10 2017-03-16 Albert Einstein College Of Medicine, Inc. Synthetic antibodies to bax and uses thereof
CA3016901C (en) * 2016-03-07 2023-06-13 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
CN113330026A (zh) 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof

Similar Documents

Publication Publication Date Title
US20230242648A1 (en) Antibodies to integrin avb6 and use of same to treat cancer
ES2523915T3 (es) Agentes de unión a la diana variantes y usos de los mismos
US9828428B2 (en) Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates
JP2022506072A5 (cg-RX-API-DMAC7.html)
JP2024535637A (ja) 抗体及びその薬物コンジュゲ-ト並びに用途
JP6454269B2 (ja) Cd33抗体及び癌を処置するためのその使用
CN107880126B (zh) 抗ntb-a抗体及相关组合物和方法
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
CN110240654A (zh) 结合cd73的抗体-药物偶联物
CN111712520A (zh) 磷脂酰肌醇聚糖3抗体及其偶联物
JP2025148380A (ja) 抗体-薬物コンジュゲート及びそれらの使用
WO2024235135A1 (zh) 大环化合物及其制备方法和用途
WO2024235130A9 (zh) 多环化合物及其制备方法和用途
JP2026512687A (ja) ヒト化l1cam抗体-薬物複合体
WO2024235131A1 (zh) 大环类药物偶联物及其制备方法和用途
WO2024236163A1 (en) T cell receptor beta constant region 2 (trbc2) antibodies
AU2024304014A1 (en) Anti-cd5 antibodies and their uses
HK1211035B (en) ANTIBODIES TO INTEGRIN αvβ6 AND USE OF SAME TO TREAT CANCER